Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Number 2: The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related ...

Swiss pharma giant Novartis (NOVN: VX) has announced a planned $23 billion investment over five years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in ...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s (LSE: AZN) Truqap (capivasertib) with fulvestrant as an option for around 1,100 adults with hormone ...

a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone ...

This would be the third indication for aflibercept 8 mg supporting the blockbuster status of Eylea. The submission is based on positive results from the global randomized, double-masked, ...

In the United States, Regeneron maintains exclusive rights to aflibercept 2 mg (Eylea 2 mg) and aflibercept 8 mg (Eylea HD); outside the US, Bayer has licensed exclusive marketing rights. According to ...

Family caregivers with both children and elderly family members to care for are reporting higher levels of burnout and mental health issues. When adults hit a certain age, they often find themselves ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the same rare immune diseases as Soliris. Amgen’s Bkemv and Teva/Samsung ...

However, the drugmaker encountered issues with one of its main growth drivers, Eylea, which treats wet age-related macular degeneration. Eylea is facing stiff competition, biosimilar and otherwise.

Roche/Genentech: Developers of Avastin (bevacizumab), often used off-label for AMD, and Eylea (aflibercept). Regeneron Pharmaceuticals: This company developed Eylea (aflibercept), a commonly ...